Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis

Lijuan Li1,*, Nan Li1,*, Wei Pang1,*, Xu Zhang2, Bruce D. Hammock3, Ding Ai2,*, Yi Zhu1,2,*

1 Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China, 2 Department of Physiology, Tianjin Medical University, Tianjin, China, 3 Department of Entomology and Comprehensive Cancer Center, University of California Davis, Davis, California, United States of America

Abstract
Arachidonic acid-derived epoxyeicosatrienoic acids (EETs) are important regulators of cardiac remodeling; manipulation of their levels is a potentially useful pharmacological strategy. EETs are hydrolyzed by soluble epoxide hydrolase (sEH) to form the corresponding diols, thus altering and reducing the activity of these oxylipins. To better understand the phenotypic impact of sEH disruption, we compared the effect of EPHX2 gene knockout (EPHX2−/−) and sEH inhibition in mouse models. Measurement of plasma oxylipin profiles confirmed that the ratio of EETs/DHETs was increased in EPHX2−/− and sEH-inhibited mice. However, plasma concentrations of 9, 11, 13, 19-HETE were elevated in EPHX2−/− but not sEH-inhibited mice. Next, we investigated the role of this difference in cardiac dysfunction induced by Angiotensin II (AngII). Both EPHX2 gene deletion and inhibition protected against AngII-induced cardiac hypertrophy. Interestingly, cardiac dysfunction was attenuated by sEH inhibition rather than gene deletion. Histochemical staining revealed that compared with pharmacological inhibition, EPHX2 deletion aggravated AngII-induced myocardial fibrosis; the mRNA levels of fibrotic-related genes were increased. Furthermore, cardiac inflammatory response was greater in EPHX2−/− than sEH-inhibited mice with AngII treatment, as evidenced by increased macrophage infiltration and expression of MCP-1 and IL-6. In vitro, AngII-upregulated MCP-1 and IL-6 expression was significantly attenuated by sEH inhibition but promoted by EPHX2 deletion in cardiofibroblasts. Thus, compared with pharmacological inhibition of sEH, EPHX2 deletion caused the shift in arachidonic acid metabolism, which may lead to pathological cardiac remodeling, especially cardiac fibrosis.

Citation: Li L, Li N, Pang W, Zhang X, Hammock BD, et al. (2014) Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis. PLoS ONE 9(4): e94092. doi:10.1371/journal.pone.0094092

Introduction
Pathophysiological cardiac remodeling, characterized by cardiac hypertrophy and interstitial fibrosis, is one of the most common causes of heart failure [1,2]. These pathophysiological changes of cardiac remodeling include hypertrophic growth and increased protein synthesis of cardiomyocytes [3] as well as hyperproliferation, collagen metabolism disorder and phenotype transforming of cardiac fibroblasts [4], which lead to contraction/dilation dysfunction and finally reduced compliance of the ventricle wall, all of which contribute to the development of heart failure. Adverse cardiac remodeling is always associated with inflammation, which plays a key role in the development and progression of cardiac fibrosis [5,6]. Proinflammatory stimuli such as Angiotensin II (AngII) or transforming growth factor β (TGF-β) treatment, hypertension and myocardial infarction lead to infiltration of inflammatory cells including macrophages, immune cells, neutrophils, mast cells and dendritic cells into the myocardium [7,8,9]. This infiltration releases numerous cytokines and chemokines, including interferon γ (IFN-γ), transforming growth factor α (TNF-α), TGF-β, and monocyte chemoattractant protein 1 (MCP-1), which may regulate further infiltration of inflammatory and neuropathic pain. Eicosanoids with no funding for this project. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

* E-mail: zhuyi@tijmu.edu.cn (YZ); edin2000cn@gmail.com (DA)

† These authors contributed equally to this work.

This infiltration releases numerous cytokines and chemokines, including interferon γ (IFN-γ), transforming growth factor α (TNF-α), TGF-β, and monocyte chemoattractant protein 1 (MCP-1), which may regulate further infiltration of inflammatory and neuropathic pain. Inflammation is a complex biological response to noxious stimuli and is characterized by leukocyte infiltration and proinflammatory cytokine production. The inflammatory response is mediated by a variety of cells, including monocytes, macrophages, neutrophils, eosinophils, basophils, mast cells and dendritic cells. The release of proinflammatory cytokines and chemokines further exacerbates myocardial injury and promotes cardiac fibrosis. Therefore, the regulation of inflammation is crucial for the prevention and treatment of heart failure.

Eicosanoids, including prostaglandins (PGs), thromboxanes (TXs) and leukotrienes (LTs), are important mediators of inflammation and play a key role in the development and progression of cardiac fibrosis. Prostaglandins are produced by cyclooxygenases (COXs) and released as metabolites of arachidonic acid (ARA). Thromboxane A2 (TXA2) and prostacyclin (PGI2) are two important prostanoids involved in the regulation of inflammation and fibrosis. TXA2, a potent vasoconstrictor, promotes smooth muscle cell proliferation and fibroblast activation, while PGI2, a vasodilator, inhibits platelet aggregation and smooth muscle cell proliferation. The balance of TXA2 and PGI2 is crucial for the prevention of myocardial fibrosis.

Acetylcholine (ACh) is a key neurotransmitter that regulates smooth muscle tone and cardiac function. The release of ACh promotes relaxation of smooth muscle cells via activation of muscarinic receptors. Inhibition of muscarinic receptors leads to smooth muscle cell contraction and fibrosis. Therefore, the regulation of ACh and muscarinic receptors is crucial for the prevention of myocardial fibrosis.

Cardiac fibrosis is a complex process involving the activation of fibroblasts, the accumulation of extracellular matrix components, and the loss of contractile function. The fibrotic process involves the recruitment and activation of inflammatory cells, including monocytes, macrophages, and T cells, which release proinflammatory cytokines and chemokines. These cytokines and chemokines further recruit and activate fibroblasts, leading to the production of collagen and other extracellular matrix components. The accumulation of extracellular matrix components results in myocardial fibrosis, which is characterized by a decrease in cardiac function and an increase in myocardial stiffness. The development of cardiac fibrosis is associated with the activation of profibrotic signaling pathways, including the renin-angiotensin system (RAS) and the transforming growth factor β (TGF-β) pathway.

The RAS plays a crucial role in the development of cardiac fibrosis. Angiotensin II (AngII), a potent vasoconstrictor, is produced by the renin-angiotensin system and is a key mediator of inflammation and fibrosis. AngII promotes fibroblast activation and collagen production, leading to cardiac fibrosis. Inhibition of the RAS with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers is effective in preventing myocardial fibrosis.

The TGF-β pathway is also involved in the development of cardiac fibrosis. TGF-β is a potent profibrotic cytokine that promotes the activation of fibroblasts and the production of extracellular matrix components. TGF-β signaling is dysregulated in patients with heart failure, leading to myocardial fibrosis. Inhibition of the TGF-β pathway with TGF-β receptor antagonists or small-molecule inhibitors is effective in preventing myocardial fibrosis.

In addition to the RAS and TGF-β pathways, other inflammatory cytokines and chemokines play a role in the development of myocardial fibrosis. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are proinflammatory cytokines that promote fibroblast activation and collagen production. Inhibition of IL-1β and TNF-α with specific blockers is effective in preventing myocardial fibrosis.

In conclusion, the regulation of inflammation and fibrosis is crucial for the prevention and treatment of heart failure. The development of novel therapeutic targets for inflammation and fibrosis is essential for the management of heart failure. Further research is needed to elucidate the mechanisms underlying the development of myocardial fibrosis and to identify effective therapeutic strategies for preventing and treating heart failure.
tion response to endotoxin inhalation by decreasing 12-HETE and 15-HETE generation [14,15,16]. In addition, CYP4A- and CYP4F-derived 20-HETE is a proinflammatory mediator of endotoxin-induced acute systemic inflammation [17] involved in the development and/or progression of inflammatory cardiovascular diseases [18] by regulating monocyte/macrophage infiltration [19]. As compared with HETEs, EETs have vessel-dilation, myocardial-protective and anti-inflammatory effects [20,21].

Soluble epoxide hydrolase (sEH) is the key enzyme hydrolyzing EETs to their corresponding dihydroxyeicosatrienoic acids (DHETs) and reducing the bioavailability of EETs [21]. Several generations of sEH inhibitors have been developed, and the administration of these drugs have beneficial effects on hypertension and cardiac dysfunction [22,23]. Disruption of sEH gene (EPHX2) does not show alteration in basal blood pressure resulting from the shift in ARA metabolism to produce more 20-HETE in kidneys in both NIH and BI colonies [24], therefore sEH deletion and inhibition may have different effects. Our previous study demonstrated that sEH expression was induced by AngII in the rodent heart, and inhibition of sEH attenuated AngII-induced cardiac hypertrophy [25]. However, whether sEH is involved in AngII-induced cardiac fibrosis is still unknown. In this study, we compared the oxylipin profile with EPHX2 deletion and sEH inhibition in mice to explore the effects of sEH in cardiac fibrosis and the underlying mechanisms. Our findings may help in understanding pathological cardiac remodeling and provide experimental evidence for sEH as a novel therapeutic target for cardiac fibrosis.

**Materials and Methods**

**Ethics Statement and Animal Experiments**

All animal experimental protocols were approved by the Peking University Institutional Animal Care and Use Committee. The investigation conformed to the Guide for the Care and Use of Laboratory Animals by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). Mice with targeted disruption of EPHX2 gene (EPHX2<sup>−/−</sup>) [26] were back-crossed onto a C57BL/6 genetic background for more than ten generations as previously described [24]. Male EPHX2<sup>−/−</sup> and their littermate control (EPHX2<sup>+/+</sup>) mice (8 weeks old, 20–25 g, Peking University Health Science Center Animal Department) were kept in a 12-hr light/dark cycle at a controlled room temperature and had free access to standard chow and tap water. On the day of surgery, EPHX2<sup>−/−</sup> and their littermate control mice were anaesthetized with a cocktail of ketamine (100 mg/kg intraperitoneal)/xylazine (5 mg/kg intraperitoneal) and implanted with a minipump (Alzet 1002) in the dorsal region to deliver AngII (1000 ng/kg/min for 14 days) or underwent a sham operation as a control. The adequacy of anesthesia was continually monitored by assessing reflexes and respiration. To examine the effect of sEH inhibition on AngII-induced hypertension, EPHX2<sup>−/−</sup> mice were divided into 4 groups for treatment (n=6 mice per group): sham surgery+ vehicle group; AngII infusion(1000 ng/kg/min)+vehicle; AngII+TUPS (1- (1-methanesulfonyl-piperidin-4-yl)- 3- (4-trifluoromethoxy-phenyl) – urea); and TUPS only. TUPS was administrated by oral gavage daily at 4.0 mg/kg/day. After 3 days, the surgery was performed, and the mice were sacrificed on day 14th after the surgery. TUPS was prepared as previous described [25]. At the end of the experiment, mice received a cocktail of ketamine (100 mg/kg intraperitoneal)/xylazine (20 mg/kg intraperitoneal) for anesthesia.

**Figure 1.** sEH deletion but not sEH inhibition upregulates the plasma level of several HETEs. Plasma concentration of ARA metabolites determined by LC-MS/MS. (A) Plasma ratio of EET to DHET. (B) Plasma concentration of 9-HETE, 11-HETE, 15-HETE and 19-HETE. Data are mean±SEM from at least 6 mice in each group (*, P<0.05).

doi:10.1371/journal.pone.0094092.g001
and euthanized; hearts were removed, blotted, and weighed to determine the ratio of heart weight to body weight.

**Immunohistochemistry**

Hearts were retrograde perfused with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde overnight, then embedded in paraffin, and serial left-ventricular (LV) sections 5 μm thick were cut along the longitudinal axis and stained with haematoxylin and eosin. Types I/III collagen in cardiac muscle was stained with picric acid–sirius red. For immunohistochemical staining of Mac3, for macrophages, after endogenous peroxidase was quenched and nonspecific reaction was blocked, sections were immunostained with a rabbit anti-Mac3 antibody (BD Pharmingen, USA) and horseradish peroxidase-conjugated secondary antibody (Life technology, USA). Diaminobenzidine tetrahydrochloride was used for color development. The resulting images were acquired by use of an Olympus CKX41 microscope and Olympus Micro software. Negative controls were species-matched IgG. The size of cardiomyocytes was determined from a mean of at least 200 cells by computer-assisted image analysis (NIH Image

| **Table 1.** Plasma arachidonic acid (ARA) metabolite concentration (pg/μl) determined by LC-MS/MS with soluble epoxide hydrolase (sEH) inhibition and deletion in mice. |
|-------------|----------------|-------------|----------------|
| **Oxylipin** | **Vehicle** | **sEH inhibition** | **sEH deletion** |
| **Epoxygenase-dependent metabolism** |  |  |  |
| 14,15-EET | 0.412±0.015 | 1.120±0.039* | 1.102±0.028* |
| 11,12-EET | 0.128±0.005 | 0.269±0.016* | 0.257±0.010* |
| 8,9-EET | 0.151±0.006 | 0.384±0.018* | 0.348±0.014* |
| 5,6-EET | 0.123±0.002 | 0.144±0.007 | 0.144±0.007 |
| **sEH-dependent metabolism** |  |  |  |
| 14,15-DHET | 0.515±0.012 | 0.346±0.015* | 0.202±0.004* |
| 11,12-DHET | 0.204±0.005 | 0.196±0.009 | 0.162±0.002* |
| 8,9-DHET | 0.279±0.007 | 0.289±0.008 | 0.217±0.005* |
| 5,6-DHET | 0.096±0.002 | 0.070±0.002* | 0.058±0.001* |
| **CYP ω-hydrolase-dependent metabolism** |  |  |  |
| 20-HETE | 0.547±0.026 | 0.691±0.069 | 0.405±0.026 |
| 19-HETE | 0.871±0.017 | 1.065±0.095 | 1.776±0.098* |
| 18-HETE | 0.549±0.013 | 0.570±0.028 | 0.537±0.016 |
| 17-HETE | 0.230±0.006 | 0.235±0.006 | 0.222±0.007 |
| 16-HETE | 0.155±0.004 | 0.236±0.014* | 0.153±0.003 |
| **CYP allylic-oxidase-dependent metabolism** |  |  |  |
| 11-HETE | 0.564±0.015 | 0.642±0.103 | 0.980±0.053* |
| 9-HETE | 0.476±0.01 | 0.567±0.017 | 0.992±0.056* |
| **LOX-dependent metabolism** |  |  |  |
| 15-HETE | 1.590±0.034 | 1.283±0.076 | 3.2±0.175* |
| 12-HETE | 15.292±0.944 | 16.565±1.564 | 13.549±0.666 |
| 8-HETE | 0.541±0.025 | 0.57±0.049 | 0.663±0.038 |
| 5-HETE | 1.379±0.053 | 1.72±0.16 | 1.507±0.056 |
| 15-oxo-ETE | NP | NP | NP |
| 5-oxo-ETE | NP | NP | NP |
| LTB4 | NP | NP | NP |
| LXA4 | NP | NP | NP |
| **COX-dependent metabolism** |  |  |  |
| TXB2 | 0.038±0.001 | 0.051±0.003 | 0.041±0.002 |
| PGE2 | 0.057±0.007 | 0.044±0.007 | 0.046±0.004 |
| PGD2 | NP | NP | NP |
| PGB2 | NP | NP | NP |
| PGF2a | NP | NP | NP |
| PGJ2 | 0.131±0.008 | 0.108±0.001 | 0.15±0.011 |
| 15-deoxy-PGJ2 | NP | NP | NP |
| 6-keto-PGF1α | 0.421±0.019 | 0.551±0.036 | 0.364±0.011 |

*p<0.05 compared with vehicle; #p<0.05 compared with with sEHI.

Data are mean±SEM from at least 6 mice in each group. NP: No peak; CYP: cytochrome P450 enzymes; COX: cyclooxygenase, LOX: lipoxygenase, PG: prostaglandin.
doi:10.1371/journal.pone.0094092.t001
Table 2. sEH inhibition blocks Angiotensin II (AngII)-induced cardiac hypertrophy and change in cardiac function in mice.

|                | sham               | AngII              |
|----------------|--------------------|--------------------|
|                | vehicle            | sEH                | vehicle            | sEH                |
| HW/BW (mg/g)   | 5.10±0.09          | 5.09±0.13          | 5.80±0.13*         | 5.26±0.10*         |
| LVW/BW (mg/g)  | 2.65±0.19          | 3.08±0.08          | 3.52±0.15*         | 2.98±0.18*         |
| LVPWd (mm)     | 0.69±0.02          | 0.75±0.02          | 0.88±0.04*         | 0.83±0.06          |
| LVPWd (mm)     | 0.99±0.04          | 1.04±0.04          | 1.31±0.05*         | 1.12±0.06*         |
| LVAWd (mm)     | 0.64±0.02          | 0.71±0.02          | 0.95±0.05*         | 0.75±0.02*         |
| LVAWd (mm)     | 0.88±0.04          | 1.01±0.03          | 1.31±0.07*         | 1.08±0.03*         |
| LVEDV (μl)     | 55.29±2.14         | 54.95±5.78         | 37.47±2.74*        | 50.30±5.44*        |
| LVESV (μl)     | 25.02±2.08         | 19.91±1.60         | 11.65±1.47*        | 18.60±2.67*        |
| LVFS (%)       | 29.37±2.12         | 33.35±1.80         | 40.68±1.37*        | 34.57±2.66*        |
| LVEF (%)       | 56.35±2.86         | 62.51±2.35         | 73.23±2.70*        | 62.13±2.98*        |

Data are mean±SEM; * p<0.05 compared with vehicle sham; # p<0.05 compared with vehicle AngII.

doi:10.1371/journal.pone.0094092.t002

Table 3. sEH deletion protects against AngII-induced cardiac hypertropy but does not affect the change in cardiac function.

|                | sham   | AngII  |
|----------------|--------|--------|
|                | sEH+/+ | sEH−/− | sEH+/+ | sEH−/− |
| HW/BW (mg/g)   | 4.91±0.11 | 5.23±0.17 | 6.14±0.23* | 5.43±0.11* |
| LVW/BW (mg/g)  | 1.93±0.08 | 2.27±0.24 | 2.99±0.18* | 2.42±0.15*  |
| LVPWd (mm)     | 0.57±0.02 | 0.61±0.02 | 0.88±0.07*  | 0.64±0.05*   |
| LVPWd (mm)     | 0.78±0.03 | 0.86±0.02 | 1.16±0.06*  | 0.88±0.07*   |
| LVAWd (mm)     | 0.55±0.03 | 0.63±0.02* | 0.95±0.08*  | 0.71±0.08*   |
| LVAWd (mm)     | 0.78±0.04 | 0.85±0.01 | 1.30±0.12*  | 0.92±0.09*   |
| LVEDV (μl)     | 53.19±2.93 | 57.25±6.27 | 41.07±3.10*  | 47.17±5.03   |
| LVESV (μl)     | 26.34±1.57 | 25.37±3.85 | 15.71±1.86*  | 21.99±4.07   |
| LVFS (%)       | 26.14±1.17 | 29.06±1.45 | 32.90±2.05*  | 28.69±2.52   |
| LVEF (%)       | 51.24±1.80 | 56.48±2.29 | 62.29±2.79*  | 55.80±3.40   |

Data are mean±SEM; * p<0.05 compared with sEH+/+ sham; # p<0.05 compared with sEH+/+ AngII.

BW: body weight; HW: heart weight; LVW: left ventricular weight; LVPWd: LV posterior wall thickness at systole; LVAWd: LV anterior wall thickness at diastolic; LVAWs: LVAW at systole; LVESV: LV end-systolic volume; LVFS: LV fractional shortening; LVEF: LV ejection fraction.

doi:10.1371/journal.pone.0094092.t003
evaporated to dryness. The residue was dissolved in 100 μl 30% acetonitrile. After vigorous mixing, samples were filtered into vials of an auto-sampler through a 0.22-μm membrane. Chromatographic separation involved an ACQUITY UPLC BEH C18 column (1.7 μm, 100×2.1 mm i.d.) consisting of ethylene-bridged hybrid particles (Waters, Milford, MA, USA). The column was maintained at 30°C and the injection volume was set to 10 μl. Solvent A was water and solvent B was acetonitrile. The gradient is given in Table S1. The mobile phase flow rate was 0.6 mL/min. Chromatography was optimized to separate ARA metabolites in 9 min. ARA metabolites were quantified by use of a 5500 QTRAP hybrid triple quadrupole linear ion trap mass spectrometer (AB Sciex, Foster City, CA, USA) equipped with a Turbo Ion Spray electrospray ionization (ESI) source. The mass spectrometer was operated using software Analyst 1.5.1. Analytes were detected using multiple reaction monitoring (MRM) scans in negative mode. The dwell time used for all MRM experiments was 25 ms. The ion source parameters were set as follows: CUR = 40 psi, GS1 = 30 psi, GS2 = 30 psi, IS = −4500 V, CAD = MEDIUM, TEMP = 500°C.

Statistical Analysis
Data are presented as mean ± SEM. The significance of variability was evaluated by unpaired two-tailed Student’s t test or one-way ANOVA with a Bonferroni multiple comparison post-test (GraphPad software, San Diego, CA). Each experiment included triplicate measurements for each condition tested, unless indicated otherwise. P<0.05 was considered statistically significant.

Others
Analysis of Cardiac Function by Echocardiography, Western Blot Analysis and Quantitative Real-Time RT–PCR (The sequences of primers are in Table S2). See Methods S1.
Figure 3. Expression of cardiac fibrosis-related genes in sEH deleted and inhibited mice with AngII infusion. (A, B) Real-time PCR analysis of mRNA expression of collagen-synthesis–related genes. COL1A1: collagen type 1, alpha 1; TGF-β: transforming growth factor β1; CTGF: connective tissue growth factor. (C, D) Real-time PCR analysis of mRNA expression of collagen-degradation–related genes. MMP2/9, matrix metalloproteinase 2/9; TIMP1/2, tissue inhibitors of metalloproteinase-1/2. Data are mean ± SEM relative to that of GAPDH from at least 6 mice in each group (*, P < 0.05).

doi:10.1371/journal.pone.0094092.g003
Figure 4. sEH inhibition blocks AngII-induced upregulation of chemokines and cytokines. (A) Cross-sections of mouse left ventricle underwent immunohistochemistry staining with anti-mac3 antibody and quantification. The mRNA level of (B) F4/80, (C) monocyte chemoattractant protein 1 (MCP-1), and (D) interleukin 6 (IL-6) in LV tissue. (E) ELISA of plasma IL-6 level. Data are mean ± SEM from at least 6 mice in each group (*, P< 0.05).

doi:10.1371/journal.pone.0094092.g004
Figure 5. EPHX2 gene deletion aggravates AngII-induced cardiac inflammation. (A) Cross-sections of mouse left ventricle underwent immunohistochemistry staining with anti-mac3 antibody and quantification. The mRNA level of (B) F4/80, (C) MCP-1, and (D) IL-6 in LV tissue. (E) ELISA of plasma IL-6 level. Data are mean ± SEM from at least 6 mice in each group (*, P<0.05).

doi:10.1371/journal.pone.0094092.g005
Results

sEH Deletion but not sEH Inhibition Shifted ARA Metabolism

To study the effect of EPHX2 gene deletion and sEH inhibition on ARA metabolism, we first determined the plasma concentration of ARA metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The plasma EET concentration was elevated to a similar extent in EPHX2−/− and sEH-inhibited mice, while that of DHETs, the metabolites of EETs, was lower in EPHX2−/− than sEH-inhibited mice (Table 1). As a result, the ratio of EET to DHET was greater in EPHX2−/− than sEH-inhibited mice. In particular, the ratio of 14, 15-EET:DHET was 1.9-fold higher in EPHX2−/− mice as compared with control but not sEH inhibition (Figure 1A). Surprisingly, EPHX2−/− gene deletion significantly increased 9-HETE (2.1-fold), 11-HETE (1.7-fold), 15-HETE (2.0-fold) and 19-HETE (2.0-fold) as compared with control but not sEH inhibition (Table 1 and Figure 1B). Therefore, although both EPHX2 gene deletion and inhibition increased the ratio of EETs to DHETs, EPHX2 gene deficiency rather than sEH pharmacological inhibition increased HETE production, which may result from the metabolic shift of ARA metabolism caused by excess EET accumulation.

Both sEH Deletion and Inhibition Protected Against AngII-induced Cardiac Hypertrophy

Because the level of 4 HETEs increased in EPHX2−/− mice was found associated with vascular remodeling by a pro-inflammatory effect [15,28,29,30,31], we next explored the different physiological effects of EPHX2 gene deletion and inhibition in a mouse cardiac hypertrophy model. EPHX2−/− and wild-type mice received sustained infusion of AngII (1000 ng/kg/min) via an implanted minipump for 14 days. SBP was measured every other day by tail cuff plethysmography and SBP was significantly increased from 100 mmHg to 150 mmHg with AngII infusion in wild-type mice, which was attenuated by EPHX2 deficiency and inhibition (Figure 1A). Surprisingly, EPHX2 gene deletion significantly increased 9-HETE (2.1-fold), 11-HETE (1.7-fold), 15-HETE (2.0-fold) and 19-HETE (2.0-fold) as compared with control but not sEH inhibition (Table 1 and Figure 1B). Therefore, although both EPHX2 gene deletion and inhibition increased the ratio of EETs to DHETs, EPHX2 gene deficiency rather than sEH pharmacological inhibition increased HETE production, which may result from the metabolic shift of ARA metabolism caused by excess EET accumulation.

Deletion of EPHX2 Aggravated AngII-induced Cardiac Fibrosis

Although sEH deletion and inhibition have similar effects on AngII-induced hypertension and cardiac hypertrophy, their effects on cardiac function were opposite. AngII infusion decreased left-ventricular (LV) end-diastolic volume and LV end-systolic volume and increased LV fractional shortening and LV ejection fraction (Table 2 and Table 3). These data suggest that the heart function was in a compensation period after 14 days of AngII infusion. When we examined the involvement of sEH in cardiac function, sEH inhibition attenuated the effects of AngII (Table 2). Interestingly, as compared with sEH inhibition, EPHX2 deletion could not reverse the AngII-induced cardiac dysfunction (Table 3).

To further analyze the phenotype of the cardiac dysfunction, we measured cardiac fibrosis in those two models by picric acid–sirius red staining. Compared with vehicle treatment, cardiac collagen deposition was prevented by 42% by administration of TUPS (Figure 2A). However, AngII-induced myocardial fibrosis was aggravated in EPHX2−/− mice (Figure 2B).

sEH Deletion and Inhibition had Opposite Effects on the Expression of Genes Related to Collagen Synthesis in the Heart

We investigated the impact of EPHX2 gene deletion and inhibition on the expression of fibrosis-related genes. AngII infusion increased the mRNA level of both collagen synthesis genes such as collagen I, pro-fibrotic cytokine connective tissue growth factor (CTGF), and Lysyl oxidase (Figure 3A, B), as well as collagen degradation genes such as matrix metalloproteinase 2 (MMP2) and tissue inhibitor of metalloproteinase 1 (TIMP-1) (Figure 3C, D). The mRNA levels of collagen I, CTGF, and Lysyl oxidase were reduced to 60%, 56%, and 68%, respectively, by sEH inhibition as compared with AngII infusion alone (Figure 3A). In contrast, EPHX2−/− mice showed significantly increased level of these genes, by 78%, 134%, and 83%, respectively (Figure 3B). Neither EPHX2 deletion nor sEH inhibition affected the expression of collagen-degradation-related genes, including MMP2/9 and their tissue inhibitors (TIMP-1/2) (Figure 3C, D), which suggests that the opposite effect of sEH deletion and inhibition on AngII-induced cardiac fibrosis is via influencing collagen synthesis rather than degradation.

EPHX2 Gene Deletion Aggravates AngII-induced Cardiac Inflammation

sEH was reported by Spector et al to be the major enzyme involved in the degradation of EETs which played an important role in myocardial inflammation [20,21]. To test whether sEH affects AngII-induced collagen synthesis process by influencing cardiac inflammation, we measured inflammation in the myocardium in vitro. The infiltration of macrophages was determined by immunohistochemistry staining with anti-Mac3 antibody. As compared with control mice, AngII infusion caused an increased number of Mac3+ cells infiltrating into heart tissue, and the phenotype was reduced by TUPS treatment (Figures 4A). Consistently, TUPS significantly decreased the mRNA level of F4/80 to 67% (Figure 4B) and the expression of inflammatory factors such as MCP-1 to 41% (Figure 4C) and IL-6 to 50% (Figure 4D) in LV tissue as compared with vehicle-treated AngII-infused mouse. Moreover, elevated plasma level of IL-6 with AngII infusion was suppressed by TUPS treatment (Figure 4E). Therefore, sEH inhibition attenuated cardiac inflammation induced by AngII.

We next evaluated the function of EPHX2 gene deletion in cardiac inflammation. Surprisingly, AngII-induced macrophage accumulation in LV tissue was aggravated in EPHX2−/− mice. Mac3+ cells in the hearts of AngII-infused EPHX2−/− mice was 158% that of control mice (Figures 5A), and the mRNA levels of F4/80 (Figure 5B), MCP-1 (Figure 5C) and IL-6 (Figure 5D) in LV tissue of AngII-infused EPHX2−/− mice were further increased by 54%, 76%, and 153%, respectively. Different from the mRNA...
level, basal level of plasma IL-6 in EPHX2−/− mice was 2.2 folds of WT control mice (Figure 5E), and EPHX2 deficiency did not further increased the levels of plasma IL-6 in AngII-infused mice which suggested that local IL-6 level rather than circulation level determined cardiac inflammation. We also tested other inflammatory cytokines such as IFNγ, TNFα and IL-1β, but there was no significant change in our model (Figure S2). Thus, sEH deletion and inhibition had opposite effects on cardiac inflammation and macrophage accumulation, which may contribute to the formation of cardiac fibrosis.

Effect of sEH on AngII-induced Production of Inflammatory Factors in Cardiomyocytes

We tested the mechanism of the difference between sEH deficiency and inhibition in an in vitro setting. As a latest generation sEH inhibitor, sEH activity was reduced dramatically by TUPS in cultured cardiac cells [25,32]. We isolated cardiomyocytes from wild-type or EPHX2−/− mice and treated the cells with AngII and/or TUPS for 24 hr, then measured the expression of collagen-synthesis–related genes and inflammatory factors. Unexpectedly, the collagen synthesis function of cardiomyocytes was not influenced by AngII or sEH deletion/inhibition (Figure 6A-D). However, the change in levels of inflammatory factors was consistent with in vivo data. Administration of AngII for 24 hr significantly increased the mRNA level of MCP-1 to 161% (Figure 6E) and IL-6 to 132% (Figure 6F) which was attenuated to control level by sEH inhibition. In contrast, EPHX2 deficiency further elevated the mRNA levels of MCP-1 and IL-6 to 214% and 227%, respectively (Figure 6E, F). Therefore, sEH participated in the process of cardiac fibrosis systemically, including via production of cardiomyocyte inflammatory factors and macrophage infiltration.

Discussion

Arachidonic acid (ARA) is a free fatty acid derived from membrane phospholipids by phospholipase A2 (PLA2) and other enzymes. It can be metabolized by COXs, LOXs, and CYPs to form many biological active eicosanoids [11]. Some ARA metabolites such as EETs and PGs have anti-inflammatory and cardioprotective roles [33,34], but many are pro-inflammatory and pro-fibrotic eicosanoids [35,36,37,38]. In this study, we investigated the relationship between sEH enzymatic activity in the blood of sEH inhibited and deficiency mice. Our LC-MS/MS data showed a higher ratio of EETs to DHETs with sEH deletion than inhibition and increased plasma concentration of 9-HETE, 11-HETE, 15-HETE and 19-HETE, which potentially eliminated the beneficial effect of EETs. Although we did not detect the change of 20-HETE, we cannot exclude it because of the possible limitation of our methods.

sEH is a homodimer consisting of two domains with two distinct activities: the N-terminal domain phosphatase activity and C-terminal epoxide hydrolase activity [39]. The C-terminal is the site of the epoxygenase-2 activity which the sEH inhibitors including TUPS are against. Although the role of phosphatase domain has yet to be fully uncovered, N-terminal may play a role in regulating cholesterol synthesis in liver [40,41] and altering the phosphorylation of endothelial nitric oxide synthase (eNOS) in endothelial cells [42]. In our study, different from partial inhibition of sEH by sEH inhibitor, global EPHX2 deficiency resulted in a total defect in the sEH metabolic pathway with higher ratio of EETs to DHETs, and the high EETs levels caused an adaption by shifting ARA metabolism to other proinflammatory pathways. Consistent with our study, Luria et al indicated that EPHX2-null mice maintained normal basal blood pressure and reduced hypotensive effects of LPS challenge by increasing renal 20-HETE production through a feedback effect on CYP4A [24]. Since beneficial effects of sEH inhibitor are dependent on C-terminal, the loss of N-terminal in EPHX2−/− mice may contribute to the opposite phenomenon observed in sEH deficient and inhibited mice. In EPHX2−/− mice, lysosphosphatidic acids (LPA) hydrolysis activity is 99% less than wild type mice [43], suggesting LPAs are the best nature substrates for sEH N-terminal. By binding to LPA receptors, LPA induced COX-2 expression and modulates proinflammatory gene expression [44]. As an inflammation mediator, recent study implicated crosstalk of the 5-LOX and COX-2 pathways as an alternative biosynthetic route of diHETEs from HETEs [45], which may explain the shift of AA metabolic profile in EPHX2−/− mice. In addition, as Luria et al shown, CYP enzymes may also be directly modulated by EETs overload which allow organisms to reduce the excess EETs and maintain homeostatic control of critical phenotypic characteristics [24]. Different from pharmacological inhibition of sEH by TUPS, although EPHX2 deletion resisted the AngII induced hypertension and cardiac hypertrophy, it aggravated the cardiac fibrosis, which has been proposed as a major determinant leading to both cardiac systolic and diastolic dysfunction [46,47] and contribute to the deterioration of cardiac dysfunction.

Our previous studies showed that in AngII-infused rat model, the sEH inhibitor TUPS could repress hypertension and the hypertrophic process [25]. However, the involvement of sEH in pathological cardiac remodeling induced by AngII, especially in the interstitial fibrosis process, was still unclear. In the current study, we evaluated cardiac fibrosis in sEH deletion and inhibited mice. Consistent with the study by Sirish and colleagues, sEH inhibition prevented AngII-induced interstitial fibrosis [48]. Surprisingly, we observed increased cardiac fibrosis in EPHX2 deletion mice. As compared with reduced collagen-synthesis gene expression caused by sEH inhibition, EPHX2 deficiency further upregulated collagen I and pro-fibrotic factors induced by AngII. However, our in vitro experiments showed that sEH did not directly affect the expression of fibrosis genes in myofibroblasts. We found that opposite to EPHX2 deficiency, administration of the sEH inhibitor TUPS effectively attenuated MCP-1 and IL-6 expression which may result in decreased macrophage accumulation. Many studies showed that inflammation plays a key role in the development and progression of cardiac fibrosis [5,6]. The inflammatory factors secreted by cardiomyocytes activate inflammatory cells such as macrophages, lymphocytes, and mast cells. Inflammatory cells infiltrating into the myocardium release numerous inflammatory factors, including IFNγ, TNFα, TGFβ and MCP-1, which further recruit inflammatory cells as well as cardiomyocytes [10]. The association of cardiac fibrosis and inflammatory response suggested that opposite effect of sEH deletion and inhibition on AngII-induced cardiac fibrosis is inflammation-dependent which may be caused by different ARA metabolism as we stated before.

In conclusion, we provide novel insights into the role of sEH in regulating AngII-induced MCP-1 and IL-6 expression and cardiac fibrosis. Different from the beneficial effect of partial sEH disruption by pharmacological inhibition, the compensation effect of total EPHX2 deficiency shifted ARA metabolism to ω-hydroxylase-LOX pathways, increased the level of pro-inflammatory factor HETEs and eliminated the anti-inflammation and cardioprotective effect of EETs. Increased MCP-1 and IL-6 expression in EPHX2 deficiency mice may promote AngII-induced macrophage infiltration which increased ECM synthesis and secretion in cardiomyocytes. Our results suggest that sEH is...
involved in pathological cardiac remodeling, especially cardiac fibrosis, depending on the way of sEH disruption. These findings may reveal a novel effect of sEH in cardiac fibrosis and have clinical significance for treatment of cardiac remodeling.

Supporting Information
Figure S1 Both sEH deletion and inhibition protected against AngII-induced cardiac hypertrophy. (A, D) Cross sections of mouse left ventricles were stained with hematoxylin and quantification of the relative cell area of cardiomyocytes was performed. (B, E) Representative images of echocardiography. (C, F) Real-time PCR analysis of the mRNA level of atrial natriuretic protein (ANP) and β-myosin heavy chain (β-MHC) in left-ventricular (LV) tissue. Data are mean ± SEM from at least 6 mice in each group (*, P < 0.05). Sham, sham infusion; sEH, sEH inhibition; –/–, EPHX2 gene deficiency.

Figure S2 Neither sEH inhibition nor EPHX2 null affected the expression of several inflammation cyto-
kines. Real-time PCR analysis of the mRNA level of interferon γ (IFNγ), tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β) in LV tissue. Data are mean ± SEM relative to that of GAPDH from at least 6 mice in each group (*, P < 0.05).

Table S1 LC gradient. (DOC)
Table S2 Primers used for real-time PCR. (DOC)
Methods S1. (DOC)

Author Contributions
Conceived and designed the experiments: YZ DA BDH. Performed the experiments: LL NL WP XZ. Analyzed the data: LL NL WP XZ. Contributed reagents/materials/analysis tools: XZ BDH. Wrote the paper: LL NL WP BDH DA YZ.

References
1. Berk BC, Fujikawa K, Lehous S (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568–575.
2. Kenchilah S, Pfeiffer MA (2004) Cardiomic remodeling in systemic hypertension. Med Clin North Am 88: 115–130.
3. Pare GC, Easlick JL, Mislow JM, McNally EM, Kapiloff MS (2005) Nesprin-null mice reveal the cardiac myocyte nucleus envelope. Exp Cell Res 303: 388–399.
4. Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 235–278.
5. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, et al. (1994) Soluble epoxide hydrolase as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol 153: 359–367.
6. Hayashidani S, Tsutsui H, Shiono T, Bruech M, Matabusa H, et al. (2003) Anti-monocyte chemotactic protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108: 2134–2140.
7. Anzai A, Anzai T, Nagai S, Maekawa Y, Nako K, et al. (2012) Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation 125: 1234–1245.
8. Ratcliffe NR, Hutchins J, Barry B, Hickey WF (2000) Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis. J Autoimmun 15: 359–367.
9. Dixon IM, Cunningham RH (2011) Mast cells and cardiac fibroblasts: accomplices in elevation of collagen synthesis in modulation of fibroblast phenotype. Hypertension 58: 142–144.
10. Levick SP, Loch DG, Todor SM, Janicki JS (2007) Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol 178: 641–666.
11. Inug JD, Hammon D (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794–805.
12. Nishimura H, Hirai A, Omura M, Tamura Y, Yoshida S (1989) Arachidonic acid metabolites by cytochrome P-450 dependent monooxygenase pathway in bovine adrenal fasciculata cells. Prostaglandins 38: 413–430.
13. Capdevila J, Marnett LJ, Chacoa N, Prough RA, Estabrook DW (1982) Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc Natl Acad Sci U S A 79: 767–770.
14. Rossaj J, Nader JL, Ley K, Zarbock A (2012) Eliminating or blocking 12/15-lipoxygenase reduces neutrophil recruitment in mouse models of acute lung injury. Crit Care 16: R166.
15. Goetzl EJ, Brash AR, Tauber AI, Oates JA, Hubbard WC (1980) Modulation of lipoxygenase-catalyzed arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Rev 61: 410–418.
16. Goetzl EJ, Hill HR, Gorman RR (1980) Unique aspects of the modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. Immunology 39: 491–501.
17. Tuerun B, Kociszewski B, Sari AN, Kazar M, Unsal D, et al. (2012) A Novel Treatment Strategy for Septis and Septis Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyicosatetraenoic Acid. Antiinflamm Antiallergy Agents Med Chem 11: 121–150.
18. Anwar-mahmood A, Zordoky BN, Absoltul ME, El-Kadi AO (2010) Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Rev 61: 410–418.
19. Hoff U, Lakitsch I, Chaykova L, Ladow M, Arnold C, et al. (2011) Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 79: 57–65.
20. Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43: 55–90.
21. Deng Y, Theken KN, Lee CR (2010) Cytochrome P450 epoxyenones, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 48: 331–341.
22. Chiamimmunovat N, Ho CM, Tsai HJ, Hammock BD (2007) The soluble epoxide hydrolase as a pharmacological target for hypertension. J Cardiovasc Pharmacol 49: 225–237.
23. Xu D, Li N, He Y, Timofeyev V, Lu L, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103: 18733–18738.
24. Luria A, Weldon SM, Kabelow AK, Ingraham RH, Matera D, et al. (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282: 2891–2896.
25. Ai D, Pang W, Li N, Xu M, Jones PD, et al. (2009) Soluble epoxide hydrolase plays an essential role in angiotension II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 106: 564–569.
26. Sinal CJ, Miyata M, Tolkin M, Nagata K, Bend JR, et al. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 45904–45910.
27. van Kesteren CA, Saris JJ, Delkens DH, Lamers JM, Saxena PR, et al. (1999) Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiac fibrocyte hypertrophy independent of angiotensin II. Cardiovasc Res 43: 148–156.
28. Zein CO, Lopez R, Fu X, Kirwan JP, Yezian LM, et al. (2012) Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology 56: 1291–1299.
29. Nie X, Song S, Zhang I, Qiu Z, Shi S, et al. (2012) 15-Hydroxyeicosatetraenoic acid (15-HETE) protects pulmonary artery smooth muscle cells from apoptosis via inducible nitric oxide synthase (NOS) pathway. Prostaglandins Other Lipid Mediat 59: 50–59.
30. Singh NK, Wang D, Kundunam-Sridharan V, Van Quyen D, Nu J, et al. (2011) 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 5 stimulation and monocyte chemoattractant protein-1 expression require renin-sensitive activation of epidermal growth factor receptor in vascular wall remodeling. J Biol Chem 286: 22478–22480.
31. Honeck H, Gross V, Erdmann B, Kargol E, Neumaier R, et al. (2000) Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension 36: 610–616.
32. Athuri S, Nse MM, Abdelhamid G, Zordoky BN, Hammo BD, et al. (2013) Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy. Br J Pharmacol 169: 1794–1807.
33. Nold K, Huy V, Ruan X, Yang R, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxyenone-derived eicosanoids. Science 285: 1276–1279.
34. Francoi H, Athirakul K, Howell D, Dash R, Mao L, et al. (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2: 201–207.
35. Kalkman EA, van Sylen RJ, van Dijk JP, Saxena PR, Schoemaker RG (1995) Chronic aspirin treatment affects collagen deposition in non-infarcted
myocardium during remodeling after coronary artery ligation in the rat. J Mol Cell Cardiol 27: 2483–2494.
36. Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT (1995) Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 76: 10D-13D.
37. Harding P, LaPointe MC (2011) Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor. Prostaglandins Leukot Essent Fatty Acids 84: 147–152.
38. Ding WY, Ti Y, Wang J, Wang ZH, Xie GL, et al. (2012) Prostaglandin E2alpha facilitates collagen synthesis in cardiac fibroblasts via an F-prostanoid receptor/protein kinase C/Rho kinase pathway independent of transforming growth factor beta1. Int J Biochem Cell Biol 44: 1051–1059.
39. Gomez GA, Morisseau C, Hammock BD, Christianson DW (2004) Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 43: 4716–4723.
40. Luria A, Morisseau C, Tsai HJ, Yang J, Inceoglu B, et al. (2009) Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. Am J Physiol Endocrinol Metab 297: E375–383.
41. EnayetAllah AE, Luria A, Luo B, Tsai HJ, Sura P, et al. (2008) Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J Biol Chem 283: 36592–36598.
42. Hou HH, Hammock BD, Su KH, Morisseau C, Kou YR, et al. (2012) N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res 93: 120–129.
43. Morisseau C, Schebb NH, Dong H, Uha A, Aronov PA, et al. (2012) Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatic acids. Biochem Biophys Res Commun 419: 796–800.
44. Gobeil F Jr, Bernier SG, Vazquez-Tello A, Brault S, Beauchamp MH, et al. (2003) Modulation of proinflammatory gene expression by nuclear lysophosphatic acid receptor type-1. J Biol Chem 278: 38875–38883.
45. Tejera N, Boeglin WE, Suzuki T, Schneider C (2012) COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes. J Lipid Res 53: 87–94.
46. Burlew BS, Weber KT (2002) Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27: 92–98.
47. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J (2006) Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48: 89–96.
48. Shin P, Li N, Liu JY, Lee KS, Hwang SH, et al. (2013) Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci U S A 110: 5618–5623.